Ticagrelor is an antiplatelet medication primarily used to reduce the risk of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS) and is marketed under the brand name Brilinta. It works by reversibly inhibiting the P2Y12 receptor on platelets, thereby preventing platelet aggregation and blood clots. Maintaining the pharmaceutical purity of Ticagrelor is essential to ensure its clinical effectiveness, safety, and compliance with regulatory standards. Impurity profiling is crucial for identifying and controlling any degradation products or synthetic by-products. Here are some of its known impurities listed below.
Showing 1 - 1 of 1 products
